134 related articles for article (PubMed ID: 23388840)
21. Temsirolimus.
Schulze M; Stock C; Zaccagnini M; Teber D; Rassweiler JJ
Recent Results Cancer Res; 2014; 201():393-403. PubMed ID: 24756806
[TBL] [Abstract][Full Text] [Related]
22. Phase I/II trial of temsirolimus combined with interferon alfa for advanced renal cell carcinoma.
Motzer RJ; Hudes GR; Curti BD; McDermott DF; Escudier BJ; Negrier S; Duclos B; Moore L; O'Toole T; Boni JP; Dutcher JP
J Clin Oncol; 2007 Sep; 25(25):3958-64. PubMed ID: 17761980
[TBL] [Abstract][Full Text] [Related]
23. Phase I/II study of the mammalian target of rapamycin inhibitor everolimus (RAD001) in patients with relapsed or refractory hematologic malignancies.
Yee KW; Zeng Z; Konopleva M; Verstovsek S; Ravandi F; Ferrajoli A; Thomas D; Wierda W; Apostolidou E; Albitar M; O'Brien S; Andreeff M; Giles FJ
Clin Cancer Res; 2006 Sep; 12(17):5165-73. PubMed ID: 16951235
[TBL] [Abstract][Full Text] [Related]
24. Phase II study of temsirolimus (CCI-779), a novel inhibitor of mTOR, in heavily pretreated patients with locally advanced or metastatic breast cancer.
Chan S; Scheulen ME; Johnston S; Mross K; Cardoso F; Dittrich C; Eiermann W; Hess D; Morant R; Semiglazov V; Borner M; Salzberg M; Ostapenko V; Illiger HJ; Behringer D; Bardy-Bouxin N; Boni J; Kong S; Cincotta M; Moore L
J Clin Oncol; 2005 Aug; 23(23):5314-22. PubMed ID: 15955899
[TBL] [Abstract][Full Text] [Related]
25. Experiences and practical conclusions concerning temsirolimus use and adverse event management in advanced renal cell carcinoma within a compassionate use program in Germany.
Gerullis H; Bergmann L; Maute L; Eimer C; Otto T
Cancer Chemother Pharmacol; 2009 May; 63(6):1097-102. PubMed ID: 18818922
[TBL] [Abstract][Full Text] [Related]
26. Exploring mammalian target of rapamycin (mTOR) inhibition for treatment of mantle cell lymphoma and other hematologic malignancies.
Coiffier B; Ribrag V
Leuk Lymphoma; 2009 Dec; 50(12):1916-30. PubMed ID: 19757306
[TBL] [Abstract][Full Text] [Related]
27. Temsirolimus in renal cell carcinoma.
Otto T; Eimer C; Gerullis H
Transplant Proc; 2008 Dec; 40(10 Suppl):S36-9. PubMed ID: 19100905
[TBL] [Abstract][Full Text] [Related]
28. Clinical trial experience with temsirolimus in patients with advanced renal cell carcinoma.
Hudes GR; Berkenblit A; Feingold J; Atkins MB; Rini BI; Dutcher J
Semin Oncol; 2009 Dec; 36 Suppl 3():S26-36. PubMed ID: 19963097
[TBL] [Abstract][Full Text] [Related]
29. Concurrent involved field radiation therapy and temsirolimus in refractory mantle cell lymphoma (MCL).
Kirova YM; Chargari C; Amessis M; Vernant JP; Dhedin N
Am J Hematol; 2010 Nov; 85(11):892. PubMed ID: 20721889
[No Abstract] [Full Text] [Related]
30. Temsirolimus in relapsed and/or refractory mantle cell lymphoma†: profile report.
Hoy SM; McKeage K
BioDrugs; 2011 Jun; 25(3):193-5. PubMed ID: 21627343
[No Abstract] [Full Text] [Related]
31. Multicenter phase II study of bortezomib in patients with relapsed or refractory mantle cell lymphoma.
Fisher RI; Bernstein SH; Kahl BS; Djulbegovic B; Robertson MJ; de Vos S; Epner E; Krishnan A; Leonard JP; Lonial S; Stadtmauer EA; O'Connor OA; Shi H; Boral AL; Goy A
J Clin Oncol; 2006 Oct; 24(30):4867-74. PubMed ID: 17001068
[TBL] [Abstract][Full Text] [Related]
32. Temsirolimus has activity in non-mantle cell non-Hodgkin's lymphoma subtypes: The University of Chicago phase II consortium.
Smith SM; van Besien K; Karrison T; Dancey J; McLaughlin P; Younes A; Smith S; Stiff P; Lester E; Modi S; Doyle LA; Vokes EE; Pro B
J Clin Oncol; 2010 Nov; 28(31):4740-6. PubMed ID: 20837940
[TBL] [Abstract][Full Text] [Related]
33. A phase 2 clinical trial of deforolimus (AP23573, MK-8669), a novel mammalian target of rapamycin inhibitor, in patients with relapsed or refractory hematologic malignancies.
Rizzieri DA; Feldman E; Dipersio JF; Gabrail N; Stock W; Strair R; Rivera VM; Albitar M; Bedrosian CL; Giles FJ
Clin Cancer Res; 2008 May; 14(9):2756-62. PubMed ID: 18451242
[TBL] [Abstract][Full Text] [Related]
34. Monoclonal antibodies for the treatment of hematologic malignancies: clinical trials in Japan.
Tobinai K
Cancer Chemother Pharmacol; 2003 Jul; 52 Suppl 1():S90-6. PubMed ID: 12819934
[TBL] [Abstract][Full Text] [Related]
35. Drug-related pneumonitis in patients with advanced renal cell carcinoma treated with temsirolimus.
Maroto JP; Hudes G; Dutcher JP; Logan TF; White CS; Krygowski M; Cincotta M; Shapiro M; Duran I; Berkenblit A
J Clin Oncol; 2011 May; 29(13):1750-6. PubMed ID: 21444868
[TBL] [Abstract][Full Text] [Related]
36. Targeting mTOR in mantle cell lymphoma: current and future directions.
Smith SM
Best Pract Res Clin Haematol; 2012 Jun; 25(2):175-83. PubMed ID: 22687453
[TBL] [Abstract][Full Text] [Related]
37. Temsirolimus, interferon alfa, or both for advanced renal-cell carcinoma.
Hudes G; Carducci M; Tomczak P; Dutcher J; Figlin R; Kapoor A; Staroslawska E; Sosman J; McDermott D; Bodrogi I; Kovacevic Z; Lesovoy V; Schmidt-Wolf IG; Barbarash O; Gokmen E; O'Toole T; Lustgarten S; Moore L; Motzer RJ;
N Engl J Med; 2007 May; 356(22):2271-81. PubMed ID: 17538086
[TBL] [Abstract][Full Text] [Related]
38. Management of adverse events of targeted therapies in normal and special patients with metastatic renal cell carcinoma.
Méndez-Vidal MJ; Martínez Ortega E; Montesa Pino A; Pérez Valderrama B; Viciana R
Cancer Metastasis Rev; 2012 Sep; 31 Suppl 1():S19-27. PubMed ID: 22821550
[TBL] [Abstract][Full Text] [Related]
39. [Update on clinical activity of CCI779 (temsirolimus), mTOR inhibitor].
Mounier N; Vignot S; Spano JP
Bull Cancer; 2006 Nov; 93(11):1139-43. PubMed ID: 17145584
[TBL] [Abstract][Full Text] [Related]
40. Temsirolimus in patients with advanced renal cell carcinoma: an overview.
Bhatia S; Thompson JA
Adv Ther; 2009 Jan; 26(1):55-67. PubMed ID: 19172239
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
